Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.

Roberts A, Lamirande EW, Vogel L, Baras B, Goossens G, Knott I, Chen J, Ward JM, Vassilev V, Subbarao K.

Viral Immunol. 2010 Oct;23(5):509-19. doi: 10.1089/vim.2010.0028.

2.

A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters.

Lamirande EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, Shieh WJ, Zaki SR, Baric R, Enjuanes L, Subbarao K.

J Virol. 2008 Aug;82(15):7721-4. doi: 10.1128/JVI.00304-08. Epub 2008 May 7.

3.

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.

Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G.

Vaccine. 2011 Sep 2;29(38):6606-13. doi: 10.1016/j.vaccine.2011.06.111. Epub 2011 Jul 14.

4.

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.

Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, Gerencer M, Brühl P, Grillberger L, Reiter M, Tauer C, Mundt W, Barrett PN.

Vaccine. 2006 Jan 30;24(5):652-61. Epub 2005 Aug 26.

PMID:
16214268
5.

Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.

Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N.

J Virol. 2014 Aug;88(15):8597-614. doi: 10.1128/JVI.00983-14. Epub 2014 May 21.

6.

PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.

Gai WW, Zhang Y, Zhou DH, Chen YQ, Yang JY, Yan HM.

Virol Sin. 2011 Apr;26(2):81-94. doi: 10.1007/s12250-011-3183-z. Epub 2011 Apr 7.

PMID:
21468931
7.

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.

Qin E, Shi H, Tang L, Wang C, Chang G, Ding Z, Zhao K, Wang J, Chen Z, Yu M, Si B, Liu J, Wu D, Cheng X, Yang B, Peng W, Meng Q, Liu B, Han W, Yin X, Duan H, Zhan D, Tian L, Li S, Wu J, Tan G, Li Y, Li Y, Liu Y, Liu H, Lv F, Zhang Y, Kong X, Fan B, Jiang T, Xu S, Wang X, Li C, Wu X, Deng Y, Zhao M, Zhu Q.

Vaccine. 2006 Feb 13;24(7):1028-34. Epub 2005 Sep 12.

PMID:
16388880
8.

Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.

Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N.

J Virol. 2015 Mar;89(6):2995-3007. doi: 10.1128/JVI.02980-14. Epub 2014 Dec 17.

9.

Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.

Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB.

PLoS One. 2012;7(4):e35421. doi: 10.1371/journal.pone.0035421. Epub 2012 Apr 20. Erratum in: PLoS One. 2012;7(8). doi:10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492.

10.

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.

See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB.

J Gen Virol. 2006 Mar;87(Pt 3):641-50.

PMID:
16476986
11.

Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.

Fett C, DeDiego ML, Regla-Nava JA, Enjuanes L, Perlman S.

J Virol. 2013 Jun;87(12):6551-9. doi: 10.1128/JVI.00087-13. Epub 2013 Apr 10.

12.

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice.

Tang L, Zhu Q, Qin E, Yu M, Ding Z, Shi H, Cheng X, Wang C, Chang G, Zhu Q, Fang F, Chang H, Li S, Zhang X, Chen X, Yu J, Wang J, Chen Z.

DNA Cell Biol. 2004 Jun;23(6):391-4.

PMID:
15231072
13.

A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.

Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S, Ishii K, Sakaguchi M, Ohnishi K, Ohshima M, Hashimoto S, Odagiri T, Tashiro M, Yoshikura H, Takemori T, Tsunetsugu-Yokota Y.

Int Immunol. 2004 Oct;16(10):1423-30. Epub 2004 Aug 16.

PMID:
15314040
14.

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.

Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y.

Vaccine. 2007 Apr 12;25(15):2832-8. Epub 2006 Oct 30.

PMID:
17092615
15.

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.

Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9. Epub 2004 Jun 21.

16.

Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.

Gai W, Zou W, Lei L, Luo J, Tu H, Zhang Y, Wang K, Tien P, Yan H.

Viral Immunol. 2008 Mar;21(1):27-37. doi: 10.1089/vim.2007.0079.

PMID:
18355120
17.

Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.

Tsunetsugu-Yokota Y, Ato M, Takahashi Y, Hashimoto S, Kaji T, Kuraoka M, Yamamoto K, Mitsuki YY, Yamamoto T, Oshima M, Ohnishi K, Takemori T.

Jpn J Infect Dis. 2007 May;60(2-3):106-12.

18.

Animal models and vaccines for SARS-CoV infection.

Roberts A, Lamirande EW, Vogel L, Jackson JP, Paddock CD, Guarner J, Zaki SR, Sheahan T, Baric R, Subbarao K.

Virus Res. 2008 Apr;133(1):20-32. Epub 2007 May 11.

19.

Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.

Lu B, Huang Y, Huang L, Li B, Zheng Z, Chen Z, Chen J, Hu Q, Wang H.

Immunology. 2010 Jun;130(2):254-61. doi: 10.1111/j.1365-2567.2010.03231.x. Epub 2010 Apr 6.

20.

Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.

Zhang CH, Lu JH, Wang YF, Zheng HY, Xiong S, Zhang MY, Liu XJ, Li JX, Wan ZY, Yan XG, Qi SY, Cui Z, Zhang B.

Vaccine. 2005 May 2;23(24):3196-201.

PMID:
15837220

Supplemental Content

Support Center